Cryosite Limited Logo

Cryosite Limited

CTE.AX

(2.2)
Stock Price

0,88 AUD

9.34% ROA

84.7% ROE

23.34x PER

Market Cap.

42.952.448,00 AUD

168.74% DER

7.95% Yield

14.59% NPM

Cryosite Limited Stock Analysis

Cryosite Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cryosite Limited Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (125.89%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 DER

The stock has a minimal amount of debt (46%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROA

The stock's ROA (6.56%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

4 Revenue Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

5 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

6 Dividend Growth

The company's dividend growth has shown a positive trajectory over the past three years, consistently increasing year after year, indicating a favorable trend for potential investors.

7 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (6) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

8 PBV

The stock's elevated P/BV ratio (16.92x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

9 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

10 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Cryosite Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cryosite Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Buy

Cryosite Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Cryosite Limited Revenue
Year Revenue Growth
2001 2.427
2002 461.000 99.47%
2003 1.902.666 75.77%
2004 2.092.836 9.09%
2005 2.955.056 29.18%
2006 4.097.100 27.87%
2007 4.722.572 13.24%
2008 6.467.582 26.98%
2009 6.158.392 -5.02%
2010 5.968.601 -3.18%
2011 6.432.973 7.22%
2012 7.757.568 17.07%
2013 8.497.803 8.71%
2014 9.171.014 7.34%
2015 9.594.375 4.41%
2016 10.043.674 4.47%
2017 5.814.121 -72.75%
2018 5.864.139 0.85%
2019 7.911.695 25.88%
2020 8.919.846 11.3%
2020 8.919.846 0%
2021 10.023.769 11.01%
2022 11.756.850 14.74%
2023 11.935.000 1.49%
2024 24.840.000 51.95%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Cryosite Limited Research and Development Expenses
Year Research and Development Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 4.654 100%
2016 17.698 73.7%
2017 47.638 62.85%
2018 50.641 5.93%
2019 0 0%
2020 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Cryosite Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2001 988.049
2002 800.000 -23.51%
2003 1.589.978 49.68%
2004 1.583.598 -0.4%
2005 1.592.496 0.56%
2006 1.840.789 13.49%
2007 1.770.895 -3.95%
2008 2.520.669 29.75%
2009 3.124.084 19.31%
2010 2.568.721 -21.62%
2011 2.621.445 2.01%
2012 2.730.012 3.98%
2013 2.451.853 -11.34%
2014 2.892.011 15.22%
2015 2.516.889 -14.9%
2016 2.571.893 2.14%
2017 2.443.217 -5.27%
2018 1.962.848 -24.47%
2019 2.036.979 3.64%
2020 2.740.785 25.68%
2020 4.049.171 32.31%
2021 3.461.514 -16.98%
2022 3.741.000 7.47%
2023 4.248.000 11.94%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Cryosite Limited EBITDA
Year EBITDA Growth
2001 -930.767
2002 -993.000 6.27%
2003 -902.982 -9.97%
2004 -661.510 -36.5%
2005 -300.709 -119.98%
2006 432.605 169.51%
2007 573.187 24.53%
2008 899.902 36.31%
2009 -5.727 15813.32%
2010 312.541 101.83%
2011 818.596 61.82%
2012 1.595.331 48.69%
2013 1.424.289 -12.01%
2014 982.992 -44.89%
2015 1.001.046 1.8%
2016 932.749 -7.32%
2017 386.663 -141.23%
2018 602.855 35.86%
2019 222.738 -170.66%
2020 2.203.061 89.89%
2020 1.149.740 -91.61%
2021 1.651.350 30.38%
2022 2.456.120 32.77%
2023 2.220.000 -10.64%
2024 6.064.000 63.39%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Cryosite Limited Gross Profit
Year Gross Profit Growth
2001 -40.890
2002 -185.515 77.96%
2003 660.128 128.1%
2004 852.323 22.55%
2005 1.236.614 31.08%
2006 1.985.407 37.71%
2007 2.395.740 17.13%
2008 3.186.096 24.81%
2009 2.984.193 -6.77%
2010 2.689.214 -10.97%
2011 3.012.795 10.74%
2012 3.848.754 21.72%
2013 4.428.871 13.1%
2014 4.612.785 3.99%
2015 4.198.720 -9.86%
2016 4.022.632 -4.38%
2017 2.945.954 -36.55%
2018 3.328.801 11.5%
2019 3.308.303 -0.62%
2020 3.948.129 16.21%
2020 3.510.575 -12.46%
2021 5.305.293 33.83%
2022 6.273.634 15.44%
2023 6.478.000 3.15%
2024 14.572.000 55.54%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Cryosite Limited Net Profit
Year Net Profit Growth
2001 -984.991
2002 -1.224.000 19.53%
2003 -1.170.000 -4.62%
2004 -950.038 -23.15%
2005 -620.311 -53.16%
2006 101.374 711.9%
2007 922.744 89.01%
2008 447.059 -106.4%
2009 7.249 -6067.18%
2010 4.612 -57.18%
2011 334.305 98.62%
2012 1.022.479 67.3%
2013 1.249.961 18.2%
2014 505.602 -147.22%
2015 455.170 -11.08%
2016 302.466 -50.49%
2017 -142.109 312.84%
2018 -244.696 41.92%
2019 -565.157 56.7%
2020 1.480.179 138.18%
2020 1.480.179 0%
2021 652.574 -126.82%
2022 1.363.831 52.15%
2023 1.409.000 3.21%
2024 3.976.000 64.56%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cryosite Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Cryosite Limited Free Cashflow
Year Free Cashflow Growth
2001 -2.045.308
2002 -1.390.099 -47.13%
2003 -307.463 -352.12%
2004 -931.867 67.01%
2005 -654.982 -42.27%
2006 -266.410 -145.85%
2007 279.714 195.24%
2008 393.756 28.96%
2009 -648.487 160.72%
2010 703.274 192.21%
2011 722.856 2.71%
2012 1.698.548 57.44%
2013 1.589.014 -6.89%
2014 1.171.182 -35.68%
2015 1.055.018 -11.01%
2016 116.264 -807.43%
2017 1.447.988 91.97%
2018 -442.687 427.09%
2019 -673.691 34.29%
2020 396.535 269.89%
2021 80.071 -395.23%
2022 1.631.686 95.09%
2023 1.187.000 -37.46%
2024 1.367.000 13.17%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Cryosite Limited Operating Cashflow
Year Operating Cashflow Growth
2001 -933.519
2002 -1.195.099 21.89%
2003 0 0%
2004 -738.719 100%
2005 -199.902 -269.54%
2006 -203.024 1.54%
2007 697.651 129.1%
2008 888.268 21.46%
2009 709.858 -25.13%
2010 977.657 27.39%
2011 1.419.354 31.12%
2012 1.880.212 24.51%
2013 1.939.671 3.07%
2014 1.584.989 -22.38%
2015 1.416.902 -11.86%
2016 474.608 -198.54%
2017 1.626.789 70.83%
2018 -261.906 721.13%
2019 -647.536 59.55%
2020 1.306.382 149.57%
2021 476.965 -173.89%
2022 2.494.879 80.88%
2023 1.488.000 -67.67%
2024 1.623.000 8.32%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Cryosite Limited Capital Expenditure
Year Capital Expenditure Growth
2001 1.111.789
2002 195.000 -470.15%
2003 307.463 36.58%
2004 193.148 -59.19%
2005 455.080 57.56%
2006 63.386 -617.95%
2007 417.937 84.83%
2008 494.512 15.48%
2009 1.358.345 63.59%
2010 274.383 -395.05%
2011 696.498 60.61%
2012 181.664 -283.4%
2013 350.657 48.19%
2014 413.807 15.26%
2015 361.884 -14.35%
2016 358.344 -0.99%
2017 178.801 -100.41%
2018 180.781 1.1%
2019 26.155 -591.19%
2020 909.847 97.13%
2021 396.894 -129.24%
2022 863.193 54.02%
2023 301.000 -186.78%
2024 256.000 -17.58%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Cryosite Limited Equity
Year Equity Growth
2001 3.868.363
2002 3.889.894 0.55%
2003 2.769.834 -40.44%
2004 3.038.890 8.85%
2005 2.477.872 -22.64%
2006 2.813.290 11.92%
2007 3.735.965 24.7%
2008 4.321.088 13.54%
2009 4.340.310 0.44%
2010 4.354.687 0.33%
2011 4.691.383 7.18%
2012 5.480.664 14.4%
2013 6.264.228 12.51%
2014 6.135.137 -2.1%
2015 3.544.435 -73.09%
2016 3.378.305 -4.92%
2017 3.148.606 -7.3%
2018 1.943.415 -62.01%
2019 -1.716.070 213.25%
2020 154.875 1208.04%
2021 819.225 81.09%
2022 1.860.937 55.98%
2023 2.782.000 33.11%
2024 1.449.000 -91.99%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Cryosite Limited Assets
Year Assets Growth
2001 4.048.063
2002 4.358.889 7.13%
2003 3.524.617 -23.67%
2004 4.402.858 19.95%
2005 4.661.088 5.54%
2006 5.113.844 8.85%
2007 6.397.666 20.07%
2008 7.248.518 11.74%
2009 7.354.556 1.44%
2010 7.682.293 4.27%
2011 8.625.134 10.93%
2012 9.770.324 11.72%
2013 11.362.227 14.01%
2014 11.192.402 -1.52%
2015 9.122.755 -22.69%
2016 9.657.279 5.53%
2017 9.827.067 1.73%
2018 7.743.679 -26.9%
2019 23.172.002 66.58%
2020 23.501.906 1.4%
2021 21.992.855 -6.86%
2022 21.502.571 -2.28%
2023 22.647.000 5.05%
2024 19.713.000 -14.88%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cryosite Limited Liabilities
Year Liabilities Growth
2001 179.700
2002 468.995 61.68%
2003 754.783 37.86%
2004 1.363.968 44.66%
2005 2.183.216 37.52%
2006 2.300.554 5.1%
2007 2.661.701 13.57%
2008 2.927.430 9.08%
2009 3.014.246 2.88%
2010 3.327.606 9.42%
2011 3.933.751 15.41%
2012 4.289.660 8.3%
2013 5.097.999 15.86%
2014 5.057.265 -0.81%
2015 5.578.320 9.34%
2016 6.278.974 11.16%
2017 6.678.461 5.98%
2018 5.800.264 -15.14%
2019 24.888.072 76.69%
2020 23.347.031 -6.6%
2021 21.173.630 -10.26%
2022 19.641.634 -7.8%
2023 19.865.000 1.12%
2024 18.264.000 -8.77%

Cryosite Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.26
Net Income per Share
0.04
Price to Earning Ratio
23.34x
Price To Sales Ratio
3.41x
POCF Ratio
14.83
PFCF Ratio
17.57
Price to Book Ratio
29.64
EV to Sales
3.23
EV Over EBITDA
14.32
EV to Operating CashFlow
14.05
EV to FreeCashFlow
16.64
Earnings Yield
0.04
FreeCashFlow Yield
0.06
Market Cap
0,04 Bil.
Enterprise Value
0,04 Bil.
Graham Number
0.16
Graham NetNet
-0.26

Income Statement Metrics

Net Income per Share
0.04
Income Quality
1.57
ROE
0.85
Return On Assets
0.09
Return On Capital Employed
0.13
Net Income per EBT
0.88
EBT Per Ebit
1.02
Ebit per Revenue
0.16
Effective Tax Rate
0.12

Margins

Sales, General, & Administrative to Revenue
0.18
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.57
Operating Profit Margin
0.16
Pretax Profit Margin
0.17
Net Profit Margin
0.15

Dividends

Dividend Yield
0.08
Dividend Yield %
7.95
Payout Ratio
0.4
Dividend Per Share
0.07

Operating Metrics

Operating Cashflow per Share
0.06
Free CashFlow per Share
0.05
Capex to Operating CashFlow
0.16
Capex to Revenue
0.04
Capex to Depreciation
0.57
Return on Invested Capital
0.47
Return on Tangible Assets
0.09
Days Sales Outstanding
40.69
Days Payables Outstanding
77.66
Days of Inventory on Hand
3.98
Receivables Turnover
8.97
Payables Turnover
4.7
Inventory Turnover
91.61
Capex per Share
0.01

Balance Sheet

Cash per Share
0,10
Book Value per Share
0,03
Tangible Book Value per Share
0.03
Shareholders Equity per Share
0.03
Interest Debt per Share
0.05
Debt to Equity
1.69
Debt to Assets
0.12
Net Debt to EBITDA
-0.79
Current Ratio
1.66
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
6335000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
73500
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cryosite Limited Dividends
Year Dividends Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cryosite Limited Profile

About Cryosite Limited

Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport, and biological storage solutions to the clinical trials, and research and pharmaceutical industry. The Cord Blood and Tissues Storage segment offers long term storage solutions for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. The company was incorporated in 1999 and is based in South Granville, Australia.

CEO
Ms. Jane Hao
Employee
25
Address
13a Ferndell Street
South Granville, 2142

Cryosite Limited Executives & BODs

Cryosite Limited Executives & BODs
# Name Age
1 Mr. Hamish George
Joint Company Secretary
70
2 Mr. Michael Austin
Joint Company Secretary
70
3 Mr. Jon Stearns
Operations Manager
70
4 Ms. Jane Hao
Chief Financial Officer
70
5 Ms. Alicia Steel
Chief Quality Officer
70

Cryosite Limited Competitors